suggested that the ratio f-PSA/total (t-) PSA (f-PSA%) allows a better discriminationbetween BPH and PCa compared with t-PSA [7] [8] [9] [10] . However, all the data concerning this problem are essentially based on investigations performed by a few cooperative groups using in-house tests. Commercial test kits for measuring f-PSA are only now being offered by several compa- [11, 12] . Several factors such as the use of different antibodies, calibrators, and test design have been discussed as reasons for this unsatisfactory situation [11] [12] [13] . However, until now, there have been no reports on the analytical and clinical reliability of commercially available tests for measuring f-PSA, and no studies have addressed the issue of whether the results obtained by different testsare comparable. The present study aims to compare a largely manually performed test based on the microtiter plate technique (CanAg#{174} PSA) with a test performed as an automated assay (Immulite#{174} Free PSA) on an analyzer with regard to their analytical and clinical performances.
Materials andMethods
PSA assays. We used the enzyme immunometric assay CanAg PSA (Ca nAg Diagnostics, Gothenburg, Sweden) and the chemiluminescent enzyme immunoassay Immulite PSA (Diagnostic Products Corp., Los Angeles, CA) for both t-PSA and f-PSA determinations and the AxSym#{174} PSA assay (Abbott Labs., Abbott Park, IL) as a comparative method for determining t-PSA.
The CanAg PSA assay is based on the direct sandwich technique.The microtiter plates are coated with streptavidin, and 25 L (for determining t-PSA) or 50 zL (for f-PSA) of the samples (calibrators, patients' samples, control materials) are incubated with 100 tL of biotinylated anti-PSA monoclonal antibodies directed against either t-PSA (free and ACT-complexed PSA) or against f-PSA alone for 1 h at room temperature with constant shaking of the plate. By this procedure, t-PSA or only f-PSA in the sample is bound as an antibody sandwich complex. The wells are then emptied, filled and emptied three times with the washing buffer supplied, and incubated as described above with 100 L of monoclonal anti-PSA antibodies labeled with horseradish peroxidase. Precision. The within-run and between-day precision data were determined with control materials and pooled sera (n = 10). Fig.  1 synoptically illustrates the between-day imprecision profiles of t-PSA and f-PSA determinations obtained with the two assays.
The Immulite assays showed a better imprecision profile for both t-PSA and f-PSA. The data for within-run precision were naturally better, but comparable (not shown here). Study materials were either pooled human serum or control materials (n = 10).
Linearity and analytical recovery. The recoveries of the serum samples serially diluted two-, four-, and eightfold and recoveries of added PSA from human serum or control material to serum from healthy men or female serum were between 91% and 112%. These results confirmed the data given in the instruction sheets. [11] [12] [13] 19] . In general, the Abbott IMx method, which corresponds to the Abbott AxSym method, has yielded PSA values lower than the Hybritech Tandem methods often used as standard tests for PSA determination [20] . However, lot-to-lot variations of the Abbott reagents explain that the PSA values measured by the Hybritech and Abbott methods may be lower or higher, but also equivalent [20] . This has to be considered when comparing the t-PSA values obtained by the three methods used in our study. Table  1 shows the characteristic data of the comparison between the Immulite and CanAg assays. The slopes prove that the Immulite assays give both higher t-PSA concentrations and lower f-PSA concentrations than the CanAg assays. Significant differences between the three groups studied are evident. The two assays reveal small correlation coefficients for comparing f-PSA concentrations and f-PSA% values. PCa, as expected, had higher t-PSA concentrations than controls and BPH patients, the f-PSA concentrations were not different in PCa patients and BPH patients. The essential result obtained by both assays was that f-PSA% values were significantly lower in PCa patients than in both controls and BPH patients, whereas the f-PSA% values obtained by both assays were not significantly different (Mann-Whitney U-test) between controls and BPH patients. Despite these differences, the individual f-PSA% values partly overlap between the groups studied (Fig. 2) ROC analysis and diagnostic validity. Fig. 3 demonstrates ROC curves of t-PSA, f-PSA, and f-PSA% obtained with the two assays to discriminate between PCa patients and BPH patients. The curves for f-PSA% values run above the curves for t-PSA and f-PSA concentrations.
The area under the f-PSA% curve of the Immulite assay (Fig. 3B) is significantly higher than the area under the t-PSA curve, demonstrating a higher discriminating power of f-PSA% than t-PSA (P <0.05). It is obvious that the measurement of f-PSA concentrations alone is without diagnostic significance.
The corresponding significance level between the areas under f-PSA% and t-PSA measured by the CanAg assays (Fig. 3A) is P = 0.087. If we select the point with the highest diagnostic efficiency (83% for the Immulite assay, 79% for the CanAg assay) as the optimal decision limit, the threshold value is 15% for the Immulite and 16% for the CanAg assay. Table 3 lists the sensitivity, specificity, and predictive values of these two assays at these points comparing the data with t-PSA alone. We used the generally accepted t-PSA threshold value of 4 .tg/L for these calculations and additionally applied the indicator combination of t-PSA and f-PSA% (Table 3 ). The diagnostic specificity and the positive predictive value in detecting PCa patients were essentially improved. 
Discussion
PSA has proved to be an invaluable marker in early detection of PCa and in monitoring patients treated either by radical prostatectomy, radiation, or hormones [21, 22] . Since increased PSA concentrations are also found in BPH and inflammatory prostatic diseases, considerable efforts have been undertaken to improve the clinical validity of PSA as a cancer marker. Various concepts have been used to eliminate the interference factors that reduce the diagnostic power of PSA, e.g., the use of age-related reference values, PSA density, and PSA velocity, as well as the quantitative differentiation of the different PSA isoforms [22, 23] .
The occurrence of various PSA forms (complexed or free) in BPH and PCa patients was briefly outlined in the introduction. that PCa cells, in contrast to prostate cells of BPH, synthesize increased amounts of ACT and thus PSA-ACT complexes preferably form early in the cancer cells [24, 25] . They [24, 25] suggested that these cellular differences would also be reflected when PSA is released into the serum and that this could explain the lower ratio of f-PSA/t-PSA in the serum of PCa patients than in patients with BPH.
Recent data suggest that the determination of PSA-ACT complex may be considerably impaired by preanalytical conditions (e.g., storage of samples) [14, 15] . Although PSA-ACT is the major portion of serum PSA apparently directly related to PCa, and experimental data provide additional support for replacing t-PSA assays with assays specific for PSA-ACT [26] , those preanalytical problems have led to the argument to abandon the PSA-ACT measurement and to prefer the determination of f-PSA/t-PSA ratio [14] . However, the determination of f-PSA% needs an assay of high analytical sensitivity to f-PSA [27] , because f-PSA is the minor portion of serum PSA. Our results show that this requirement is fulfilled by both assays, since the lower detection limits were 0.004 gfL for the Immulite assay and 0.03 8 g/L for the CanAg assay. The corresponding lower detection limits of 0.014 and 0.08 g/L obtained with the female serum pool can be considered biological detection limits. We believe that the low limits obtained with the zero calibrator solution allow the use of female serum as samples to estimate the biological detection limit. Vessella et al. [28, 29] introduced the concept of biological detectionlimit by measuring PSA concentrations at the level of the lower detection limit +2 SD. These data, together with the other analytical performance characteristics such as precision, linearity, and analytical recovery, prove that both tests are sufficiently reliable. However, the automated Immulite assays showed significantly better precision than the CanAg test.
Comparison of the two tests by regression analysis (Table 2) demonstrates that values produced by the two systems are not very well compatible.
Wu [12] , in his review on the nonresolved analytical problems of PSA determination, pointed out that the generally known pitfalls in t-PSA determination must also be considered when measuring f-PSA. It is likely that the insufficient compatibility of PSA values between different commercial assays will be still more distinct if f-PSA% is to be determined, since f-PSA% values result from two different PSA determinations. For example, an accurate determination presupposes an equimolar recordingof PSA irrespective of itsoccurringin the serum in a free or complexed form [30] . Since both assays claim to be equimolar tests, the different slopes of the regression lines of f-PSA and t-PSA suggest that these differences are due to calibration. It is understandable that the compatibility of f-PSA values also needs standardization, as is being discussed for t-PSA should use only t-PSA and f-PSA assays from the same manufacturer and not apply f-PSA and t-PSA assays from different manufacturers; (b) cutoff limits of f-PSA% are assay-specific and cannot be transferred from one assay to another. A few authors were not able to prove the mentioned differences between BPH and PCa patients [35, 36] . Other authors doubt that the concept of complexed and free PSA is a useful diagnostic tool [37] . Assumed reasons for these negative results are methodological difficulties (e.g., quality of antibodies for f-PSA or PSA-ACT complex; detrimental effect of storage on samples) and inadequate consideration of assay-specific cutoff limits of f-PSA/t-PSA or PSA-ACT/t-PSA ratios. Conclusions drawn on the basis of PSA-ACT determinations should be interpreted with caution because PSA-ACT complexes dissociate during storage [14] . This may be one reason why the f-PSAJ t-PSA ratio is more sensitive for differentiating PCa and BPH than the PSA-ACT/t-PSA ratio [5] . However, since we froze serum samples at -80 #{176}C within 2 h after collection of blood samples and since we used only samples stored no longer than 8 months, we were able to exclude potential pitfalls such as the loss of PSA immunoreactivity or the dissociation of PSA-ACT complex to the greatest possible extent [14] . We show here for the first time that results described by numerous working teams [1-4, 7, 9, 13, 34, 38] using in-house f-PSA tests were confirmed by the two commercial tests used in our study. Our data prove that PCa patients show a significantly lower ratio of f-PSA/t-PSA compared with BPH patients and healthy men. In contrast to the early studies on the molecular PSA forms that included patients with a wide spectrum of t-PSA [5, 14] , we studied only men with PSA concentrations to 20 pgfL. We believe that such a limitation is well-founded because of known epidemiological data. t-PSA values of >4 j.Lg/L have been generally accepted as a general guideline for biopsy [39] . However, age-dependent reference ranges will be increasingly used [40J. Studies on >6000 men for >50 years showed a positive predictive value of 22.4-26.5% for t-PSA values ranging between 4.1 and 10 .tg/L. At PSA values >10 ,ug/L, positive predictive values were 50-67% [22] . On the other hand, -20%
of patients with positive biopsy results of PCa had t-PSA concentrations <4 j.LgIL [22] . Upon finishing our experiments, two papers came to our attention in which again results of two studies with noncommercial tests were summarized [8, 9] . These studies included patients with PSA concentrations 10 ,.tg/L. The analytical and clinical results reported were similar to those described by us. However, the cutoff limits given in the two papers differ. The data presented in those papers draw attention to the fact that, in addition to the obvious assay-specific dependence of cutoff limits, the respective approach to define the cutoff limits must be taken into account. Whereas
Oesterling et al. [8] recommended a normal f-PSA/t-PSA of >0.15
based on the concept of the 95th percentiles, Catalona et al. [9] selected the f-PSA% cutoff to maintain at least 90% sensitivity for PCa detection. The value depended on the size of the gland, such that in men with an enlarged gland, a f-PSA% cutoff value of 23.4% was recommended [9] . We used another approach and selected as cutoff limits the points with the highest diagnostic efficiency to obtain both high diagnostic sensitivity and high diagnostic specificity. These limits were 15% for the Iminulite assay and 16% for the CanAg assay. \'Vhen we used these limits alone or in combination with t-PSA, all diagnostic indicators improved con-spared with t-PSA alone. Thus, whatever approach was selected for establishing cutoff limits for f-PSA%, numerous recent results have shown that the determination of f-PSA% improves the specificity for PCa detection.
Our results demonstrate that the specificity and the positive predictive value increased by -20-40% (Table 3) . Measurement of f-PSA% may reduce the number of prostate biopsies required and may be useful in further improving the evaluation of patients at risk for PCa [8, 9] .
In conclusion, our data have proven that the two commercial test kits for measuring f-PSA-the largelymanually performed CanAg assay and the automated Immulite assay-warrant comparable analytical performance and diagnostic validity. Both are suited to improve the specific detection of PCa and support incorporating the f-PSA% measurement into the diagnostic program for the detection of PCa. Various other commercial assays for the measurement of f-PSA have been already introduced into the market or will be available in the near future. However, clinicians and clinical chemists should be aware that these tests need to be carefully tested, and that assay-specific cutoff limits must be used, because the standardization of f-PSA and t-PSA measurements
has not yet been done.
This work was supported by grants from the Faculty of Medicine at Humboldt University Berlin, Berlin, Germany and from the Fonds der Chemischen Industrie (Kj., project no. 400770). We thank Silke Klotzek and Susanne Korlach for skillful technicalassistance. The study contains part of the doctoral thesis of C.S.
